Experience

The University of Chicago Pritzker School of Medicine

• United States
• Hospitals and Health Care
• 100 - 200 Employee

• MD/PhD (MSTP) Student

  • Jun 2022 - Present

  Graduate student - year 1 Graduate student - year 1



Broad Institute of MIT and Harvard

• Research Services
• 700 & Above Employee

• Proteomics Research Associate II

  • Jan 2020 - May 2022

  As an RA on the proteomics platforms I worked within a highly matrixed team of scientists and data analysts to study the role of HLA presented peptides in various disease states including: SARS-CoV-2, Crohn’s Disease, and Lung Adenocarcinoma. At the Broad I learned to work with multi-omics data, co-authored publications, and developed new methods for analyzing low input immunopeptidomics samples. As an RA on the proteomics platforms I worked within a highly matrixed team of scientists and data analysts to study the role of HLA presented peptides in various disease states including: SARS-CoV-2, Crohn’s Disease, and Lung Adenocarcinoma. At the Broad I learned to work with multi-omics data, co-authored publications, and developed new methods for analyzing low input immunopeptidomics samples.



Northeastern University

• United States
• Higher Education
• 700 & Above Employee

• Laboratory Teaching Assistant

  • Sep 2019 - Jan 2020

  As a Laboratory Teaching Assistant for General Biology II I led undergraduate students through labs, taught them new lab techniques, held office hours, and provided individualized help as needed As a Laboratory Teaching Assistant for General Biology II I led undergraduate students through labs, taught them new lab techniques, held office hours, and provided individualized help as needed



Antimicrobial Discovery Center - The Lewis Lab

• Research Assistant

  • Sep 2017 - Jan 2020

  The Antimicrobial Discovery Center studies persister cells, unculturable bacteria, and Lyme Disease. I worked with post-doc Kirsten Meyer to examine how persister cells in S. aureus biofilms contribute to antibiotic resistance. We also studied the role of dosing regimens in improving antibiotic efficacy. Techniques used include fluorescent microscopy and microfluidics. The Antimicrobial Discovery Center studies persister cells, unculturable bacteria, and Lyme Disease. I worked with post-doc Kirsten Meyer to examine how persister cells in S. aureus biofilms contribute to antibiotic resistance. We also studied the role of dosing regimens in improving antibiotic efficacy. Techniques used include fluorescent microscopy and microfluidics.



Instituto de Medicina Molecular

• Portugal
• Research
• 300 - 400 Employee

• Research Assistant

  • Jan 2019 - May 2019

  The João Barata lab at iMM is dedicated to understanding the role of IL-7R in T-cell lymphoblastic leukemia (T-ALL). While there I worked with post-doc Bruno Cardoso to understand the role of an oncogene in T-ALL and how it impacted transcription, resistance to chemotherapy, cell proliferation, and cell viability. The João Barata lab at iMM is dedicated to understanding the role of IL-7R in T-cell lymphoblastic leukemia (T-ALL). While there I worked with post-doc Bruno Cardoso to understand the role of an oncogene in T-ALL and how it impacted transcription, resistance to chemotherapy, cell proliferation, and cell viability.



Neon Therapeutics

• United States
• Biotechnology Research
• 1 - 100 Employee

• Research Assistant

  • Jan 2018 - Aug 2018

  Neon Therapeutics was a biotechnology company acquired by BioNTech that manufactured individualized cancer vaccines and T cell therapies. I was a member of the select group, which focused on creating therapies that can help a wide range of people by targeting frequently occurring mutations in cancer patients. My job was to validate potential targets with primary cell culture and T-cell assays. Neon Therapeutics was a biotechnology company acquired by BioNTech that manufactured individualized cancer vaccines and T cell therapies. I was a member of the select group, which focused on creating therapies that can help a wide range of people by targeting frequently occurring mutations in cancer patients. My job was to validate potential targets with primary cell culture and T-cell assays.